{"id":130476,"date":"2022-06-06T10:53:31","date_gmt":"2022-06-06T14:53:31","guid":{"rendered":"https:\/\/44.250.171.167\/?p=130476"},"modified":"2022-10-06T04:26:48","modified_gmt":"2022-10-06T08:26:48","slug":"aurobindo-pharma-limited-q4-fy22-earnings-conference-call-insights","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/aurobindo-pharma-limited-q4-fy22-earnings-conference-call-insights\/","title":{"rendered":"Aurobindo Pharma Limited Q4 FY22 Earnings Conference Call Insights"},"content":{"rendered":"<p><iframe loading=\"lazy\" title=\"AUROBINDO PHARMA LTD Q4 FY22 Earnings Concall\" width=\"500\" height=\"375\" src=\"https:\/\/www.youtube.com\/embed\/ZZNGEHlRimc?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/p>\n<p><strong>Key highlights from Aurobindo Pharma Limited (<a href=\"https:\/\/44.250.171.167\/symbol\/AUROPHARMA\/\">AUROPHARMA<\/a>) Q4 FY22 Earnings Concall<\/strong><\/p>\n<p><strong>Management Update:<\/strong><\/p>\n<ul>\n<li>AUROPHARMA received final approval for 3 ANDAs and launched 4 products in 4Q22. The company also filed 14 ANDAs, including 3 Injectables during 4Q. The total number of filings at the end of March \u201822 was 727.<\/li>\n<\/ul>\n<p><strong>Q&amp;A Highlights:<\/strong><\/p>\n<ul>\n<li>Nimesh Patel of JP Morgan asked about the guidance for future. Santhanam Subramanian CFO replied that as a policy, the company doesn\u2019t give guidance.<\/li>\n<\/ul>\n<ul>\n<li>Neha Manpuria with Bank of America enquired about gross margin trends. P.V. Ram Prasad Chairman replied that the current trends may continue for a couple of quarters and the company is trying to see how to improve upon it.<\/li>\n<\/ul>\n<ul>\n<li>Neha Manpuria with Bank of America asked that on the API front if the company has been able to pass on the cost increases seen in last few months to the customers. P.V. Ram Prasad Chairman said that in terms of the domestic industry, AUROPHARMA has been able to pass on a significant portion of it.<\/li>\n<\/ul>\n<ul>\n<li>Neha Manpuria with Bank of America enquired about the oral solid business in the US in terms of price erosion. Yugandhar Puvvala CEO said that the price erosion is continuing little bit. Average in the whole year it is 9%. 4Q it is 11.5%. Between Q3 to Q4 around 2%, 2.5% was further erosion and the company expects this may not stop here.<\/li>\n<\/ul>\n<ul>\n<li>Kunal Randeria of Edelweiss asked about acquisition strategy. P.V. Ram Prasad Chairman said at present and in future the company is not into very big acquisitions at least for the next 2-3 years. AUROPHARMA wants to complete the existing projects. So the company has to protect the cash to the existing approved pending projects as well as the completion of the existing projects and the projects completed operationally breakeven and profitable projects.<\/li>\n<\/ul>\n<ul>\n<li>Kunal Dhamesha asked that on the US price erosion, if the company has done any withdrawals from the market. P.V. Ram Prasad Chairman replied that as on today the company has not withdrawn any product. And based on the situation in next 2-3 quarters, it will be informed if any.<\/li>\n<\/ul>\n<ul>\n<li>Vishal Manchanda of Nirmal Bang \u00a0asked about the capacity utilization for the oral solid manufacturing unit at a consolidated level. \u00a0P.V. Ram Prasad Chairman said that in US plants nothing has started production. In New Jersey, the new B Block oral plant is going to start production in end of \u201823. And dermatology and MDIs and patches is the plant the company is starting.<\/li>\n<\/ul>\n<ul>\n<li>Vishal Manchanda of Nirmal Bang asked that on R&amp;D, if the company would be at same level going forward as 7.5% of sales in 4Q22. P.V. Ram Prasad Chairman said that going forward the company many not be having this much of percentage, it will be around 6% is what AUROPHARMA is expecting.<\/li>\n<\/ul>\n<ul>\n<li>Vishal Manchanda of Nirmal Bang also asked about ARV business, if it will bounce back to the FY21 levels. K. Nityananda Reddy VC replied that at this juncture the company expects the business to be maintained at the same level.<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Key highlights from Aurobindo Pharma Limited (AUROPHARMA) Q4 FY22 Earnings Concall Management Update: AUROPHARMA received final approval for 3 ANDAs and launched 4 products in 4Q22. The company also filed 14 ANDAs, including 3 Injectables during 4Q. The total number of filings at the end of March \u201822 was 727. Q&amp;A Highlights: Nimesh Patel of [&hellip;]<\/p>\n","protected":false},"author":1767,"featured_media":125416,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[9825,392,5747],"tags":[1115],"class_list":["post-130476","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-earnings-call-highlights","category-earnings","category-healthcare-stocks","tag-pharmaceuticals"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":133712,"url":"https:\/\/alphastreet.com\/india\/aurobindo-pharma-limited-q1-fy23-earnings-conference-call-insights\/","url_meta":{"origin":130476,"position":0},"title":"Aurobindo Pharma Limited Q1 FY23 Earnings Conference Call Insights","author":"Praveen","date":"September 2, 2022","format":false,"excerpt":"https:\/\/youtu.be\/b8g7f6BUs9Y Key highlights from Aurobindo Pharma Limited (AUROPHARMA) Q1 FY23 Earnings Concall Q&A Highlights: [00:08:34] Prakash Agarwal of Axis Capital asked about the price erosion trends. Ram Prasad Chairman replied that the company is seeing some kind of tapering and believes the price erosion in 1Q23 vs 4Q22 is 2%\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":128559,"url":"https:\/\/alphastreet.com\/india\/glenmark-life-sciences-limited-q4-fy22-earnings-conference-call-summary\/","url_meta":{"origin":130476,"position":1},"title":"Glenmark Life Sciences Limited Q4 FY22 Earnings Conference Call Summary","author":"Praveen","date":"April 21, 2022","format":false,"excerpt":"https:\/\/youtu.be\/au71QUL41tY Key highlights from Glenmark Life Sciences Limited (GLS) Q4 FY22 Earnings Concall Q&A Highlights: Neha Manpuria of Bank of America asked if GLS is seeing any issues relative to sourcing of raw materials due to lockdown in China. Yasir Rawjee MD said that the crisis is unlikely to impact\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":129444,"url":"https:\/\/alphastreet.com\/india\/cipla-limited-q4-fy22-earnings-conference-call-insights\/","url_meta":{"origin":130476,"position":2},"title":"Cipla Limited Q4 FY22 Earnings Conference Call Insights","author":"Praveen","date":"May 11, 2022","format":false,"excerpt":"https:\/\/www.youtube.com\/watch?v=I-Ubq3MAmzg Key highlights from Cipla Limited (CIPLA) Q4 FY22 Earnings Concall Management Update: CIPLA said it crossed the $1 billion milestone in its domestic-branded prescription business, driven by the sustained growth across the company\u2019s acute and chronic portfolios. Q&A Highlights: Prakash Agarwal from Axis Capital asked about the outlook of\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":140759,"url":"https:\/\/alphastreet.com\/india\/aurobindo-pharma-limited-nse-auropharma-q3-fy23-results-out-total-income-rises-7-yoy\/","url_meta":{"origin":130476,"position":3},"title":"Aurobindo Pharma Limited (NSE: AUROPHARMA): Q3 FY23 Results Out; Total Income Rises 7% YoY","author":"Divyansh_Kasana","date":"February 9, 2023","format":false,"excerpt":"Aurobindo Pharma Limited (NSE: AUROPHARMA) is a pharmaceutical company based in Hyderabad, India. The company was founded in 1986 and has since grown to become one of the largest pharmaceutical companies in India, with a presence in over 150 countries. Aurobindo Pharma produces a wide range of generic and specialty\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/b7778d7c-e8b5-4ee8-8702-740018666b7d.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/b7778d7c-e8b5-4ee8-8702-740018666b7d.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/b7778d7c-e8b5-4ee8-8702-740018666b7d.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/b7778d7c-e8b5-4ee8-8702-740018666b7d.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/b7778d7c-e8b5-4ee8-8702-740018666b7d.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/b7778d7c-e8b5-4ee8-8702-740018666b7d.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":130444,"url":"https:\/\/alphastreet.com\/india\/aurobindo-pharma-ltd-auropharma-q4-fy22-earnings-concall-transcript\/","url_meta":{"origin":130476,"position":4},"title":"Aurobindo Pharma Ltd (AUROPHARMA) Q4 FY22 Earnings Concall Transcript","author":"Staff Correspondent","date":"June 1, 2022","format":false,"excerpt":"Aurobindo Pharma Ltd (NSE: AUROPHARMA) Q4 FY22 Earnings Concall dated May 30, 2022 Corporate Participants: Deepthi Thakur\u00a0--\u00a0Investor Relations Santhanam Subramanian\u00a0--\u00a0Chief Financial Officer P. V. Ram Prasad Reddy\u00a0--\u00a0Aurobindo Pharma USA Yugandhar Puvvala\u00a0--\u00a0CEO of Eugia Pharma Specialties Limited Nithyananda Reddy\u00a0--\u00a0Vice Chairman & Managing Director Satakarni Makkapati\u00a0--\u00a0CEO of Aurobindo Biosimilars, Vaccines and Peptides\u2026","rel":"","context":"In &quot;Earnings Call Transcripts&quot;","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"stock earnings conference call transcript","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/02\/EarningsTranscript.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/02\/EarningsTranscript.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/02\/EarningsTranscript.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":148142,"url":"https:\/\/alphastreet.com\/india\/aurobindo-pharma-limited-auropharma-q4-fy23-earnings-concall-transcript\/","url_meta":{"origin":130476,"position":5},"title":"Aurobindo Pharma Limited (AUROPHARMA) Q4 FY23 Earnings Concall Transcript","author":"IRS_INDIA","date":"May 29, 2023","format":false,"excerpt":"Aurobindo Pharma Limited (NSE:AUROPHARMA) Q4 FY23 Earnings Concall dated May. 28, 2023. Corporate Participants: Deepti Thakur -- Investor Relations & Corporate Communications Santhanam Subramanian -- Chief Financial Officer Satakarni Makkapati -- Chief Executive Officer, Aurobindo Biosimilars, Vaccines and Peptides. Yugandhar Puvvala -- Chief Executive Officer, Eugia Pharma Specialties Limited Swami\u2026","rel":"","context":"In &quot;Earnings Call Transcripts&quot;","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/130476","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1767"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=130476"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/130476\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/125416"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=130476"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=130476"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=130476"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}